Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up prior to trading on Wednesday . The stock had previously closed at $26.01, but opened at $27.63. Ascentage Pharma Group International shares last traded at $28.17, with a volume of 6,079 shares.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AAPG. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a report on Monday, November 24th. BTIG Research assumed coverage on Ascentage Pharma Group International in a report on Monday, November 10th. They set a “buy” rating and a $50.00 price target for the company. Oppenheimer started coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price objective on the stock. Piper Sandler assumed coverage on Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price for the company. Finally, Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company’s stock. According to MarketBeat, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus target price of $48.50.

Ascentage Pharma Group International Trading Down 1.2%

The business has a 50-day simple moving average of $30.29 and a 200-day simple moving average of $36.29. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AAPG. Mirae Asset Global Investments Co. Ltd. bought a new position in Ascentage Pharma Group International during the third quarter valued at $96,000. ABC Arbitrage SA bought a new position in Ascentage Pharma Group International during the 3rd quarter valued at about $204,000. Chevy Chase Trust Holdings LLC purchased a new stake in Ascentage Pharma Group International in the 2nd quarter worth about $227,000. Citadel Advisors LLC bought a new stake in Ascentage Pharma Group International in the third quarter worth about $383,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the second quarter valued at approximately $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.